

Care Pathway Update – HIV PrEP Added

WHEN: Tuesday, December 3, 2024

WHERE: The change will affect the following venue(s):

- Inpatient (Hospitalist and Women's Health Only)
- Ambulatory Women's Health
- Primary Care and Pediatrics
- Behavioral Health
- Ambulatory Orthopedics
- Walk in Care

At the following NLH Member Organization(s):

- All Member Organizations (Excluding Mayo)

WHO: The change will affect the following staff at the above noted locations:

- Physicians, NPs, PAs, Midwives
- Nurses and MAs


WHAT: The **HIV PrEP** Care Pathway will be added to all MPages that view the Care Pathways component.

WHY: The new **HIV PrEP Care Pathway** will be available to provide best practice recommendations to evaluate and identify risk factors to ensure safe and appropriate treatment is given when identified.

HOW: From the **Care Pathway** component, select **Open** in the Active Pathways **HIV PrEP**.

Guided Treatment

- HIV PrEP – Open to Start
 - Review General considerations and select resources reviewed.
- HIV PrEP Evaluation Risk
 - Select appropriate behavior identified.



NOTE: Patients below the age of 18, will refer to Pediatric ID.

- **HIV PrEP** PreTreatment Evaluation/Testing
 - Once reviewed, testing and evaluation orders will populate.
 - Select all tests/evaluations required prior to starting treatment.

NOTE: STI testing – patients should be screened for all locations of contact for common bacterial STIs.

HIV PrEP PreTreatment Evaluation/Testing	of the Care Pathway!
<p>Reassess</p> <p>Recommended baseline testing Hide Reference Text PRETREATMENT EVALUATION Testing and Evaluation needed for patients prior to starting treatment: 1. All patients need to have HIV testing and must be negative</p> <p>Other testing needed prior to initiation of PrEP</p> <p>2. STI testing – patients should be screened for all locations of contact for common bacterial STIs</p> <ul style="list-style-type: none"> • Hepatitis B screening (triple panel)/Hepatitis C screening • Gonorrhea • Chlamydia • Syphilis <p>3. Pregnancy test for all patients with reproductive potential</p> <p>4. Kidney function – to determine which treatment regimen option is appropriate (GFR/CrCl must be > 60 for Truvada (TDF-FTC) to be an option)</p> <p>5. Urinalysis for baseline proteinuria and glycosuria for those with renal disease (diabetes, hypertension, age >40, nephrotoxic medications, etc.)</p>	<p>HIV-1 RNA Quantitative By PCR BLOOD, Routine, Order for Future Visit (Select NO for Quest) In Approximately 1 Days, ONCE</p> <p>HIV-1/2 Combo Ag/Ab EIA Reflexive Panel BLOOD, Routine, Order for Future Visit (Select NO for Quest) In Approximately 1 Days, ONCE</p> <p>AMB Follow Up Appointment 2 Weeks, Provider, to review lab results</p> <p>Referral Order Medical Service: Infectious Disease</p> <p>If risk factors identified for patient below age 18 contact/refer to Pediatric ID</p> <p>Referral Order Medical Service: Pediatric Infectious Disease, Reason: HIV PrEP risk factors identified for patient below age 18</p>
<p>HIV testing recommendations reviewed ✓</p> <p>Additional testing recommendations reviewed ✓</p>	

- HIV PrEP Treatment Options
 - If pursuing PrEP, Risk factor review **MUST** be done to determine medication option.
 - When risk factor **INCLUDES** receptive vaginal sex or is undisclosed, **TDF-FTC (Truvada) is the only treatment option.**
 - If risk factor **EXCLUDES** receptive vaginal, **TDF-FTC (Truvada) and TAF-FTC (Descovy)** are both options for treatment.

NOTE: Kidney function – to determine which treatment regimen option is appropriate (GFR/CrCl must be > 60 for Truvada (TDF-FTC) to be an option).

Drug-Drug and Drug-Food Interactions

- There are significant drug-drug and drug-food interactions with PrEP antiretroviral medications. Review and discuss full medication list and over the counter medications with the patient, including NSAIDS, vitamins, and herbal supplements.
 - To view Integrase Inhibitors and Cations, click [here](#).
 - To view Food Considerations for Oral Antiretrovirals, click [here](#).
 - It is highly [recommended](#) to use the Liverpool HIV interaction [checker](#).

- HIV PrEP Management

- Verification of appropriate medication option based on risk factor behavior.

- When receptive of vaginal sex or undisclosed is selected, the recommendation for Oral TDF-FTC (Truvada) and dose will automatically be selected based on current guidelines.

The screenshot shows a web interface for 'HIV PrEP Management'. It includes a 'Reassess' button, a section for 'Verification of appropriate medication option based on risk factor behavior.' with a checkmark, and a section for 'Patient currently taking' with a 'Show Reference Text' link. The medication 'Oral Tenofovir disoproxil fumarate 300 mg-emtricitabine 200 mg TDF-FTC (Truvada)' is listed with a checkmark and a 'Save' button at the bottom right.

NOTE: /carepathways auto text needs to be included in the clinical note after completion of the Care Pathway.

Click [here](#) for additional information on how to complete a care pathway.

****PLEASE NOTE: This mailbox is not monitored.****

[Please direct any questions to the Health Informatics team using this link.](#)

If you no longer wish to receive these communications, please notify [Health Informatics Leadership](#).

If you are receiving this communication as part of a department distribution list, please reach out to the owner of that list to be removed, if appropriate.